Optimal use of diuretics in patients with heart failure

Current Treatment Options in Cardiovascular Medicine

Volumn 9, Issue 4, 2007, Pages 332-342

  Patel, Jigar ^b   Smith, Michael ^b   Hey, J Thomas ^a  

^a SCRIPPS CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE RECEPTOR BLOCKING AGENT; AMILORIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUMETANIDE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; ETACRYNIC ACID; FUROSEMIDE; HYDROCHLOROTHIAZIDE; INOTROPIC AGENT; LOOP DIURETIC AGENT; METOLAZONE; PLACEBO; POTASSIUM SPARING DIURETIC AGENT; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TOLVAPTAN; TORASEMIDE; VASOPRESSIN RECEPTOR ANTAGONIST;

ADD ON THERAPY; BOLUS INJECTION; CLINICAL TRIAL; CONTINUOUS INFUSION; DIURETIC ACTIVITY; DOSE KIDNEY FUNCTION RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; FLUID RETENTION; GYNECOMASTIA; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPERURICEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; KIDNEY DYSFUNCTION; LUNG EDEMA; MYALGIA; OTOTOXICITY; REVIEW; SIDE EFFECT; THIAMINE DEFICIENCY; TREATMENT CONTRAINDICATION; ULTRAFILTRATION; VEIN OCCLUSION;

EID: 34547512239     PISSN: 10928464     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11936-007-0028-z     Document Type: Review

References (60)

1. Cohn JN, Archibald DG, Ziesche S, et al.: Effect of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J Med 1986, 314:1547-1552.
2. The effect of digoxin on mortatity and morbidity in patients with heart failure, The Digitalis Investigation Group [no authors listed]. N Engl J Med 1997, 336:525-533.
3. Raftery EB: Haemodynamic effects of diuretics in heart failure. Br Heart J 1994, 72(suppl):S44-S47.
4. Cooper HA, Dries DL, Davis CE, et al.: Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 1999, 100:1311-1315.
5. lkram H, Chan W, Espiner EA, Nicholls MG: Haemodynamic and hormone responses to acute and chronic furosemide therapy in congestive heart failure. Clin Sci 1980, 59:443-447.
6. Bayliss J, Norell M, Canepa-Anson R, et al.: Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J 1987, 57:17-22.
7. Eshaghian S, Horwich TB, Fonarow GC: Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 2006, 97:1759-1764.
8. Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999, 341:709-717.
9. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult-Summary Article [no authors listed]. J Am Coll Cardiol 2005, 46:1116-1143.
10. Dirks JH, Sutton RA, eds: Diuretics: Physiology, Pharmacology and Clinical Use. Philadelphia: W.B. Saunders Co.; 1986.
11. Brater DC: Pharmacodynamic considerations in the use of diuretics. Ann Rev Pharmacol Toxicol 1983, 23:45-62.
12. Loon NR, Wilcox CS, Unwin RJ: Mechanism of impaired natriuretic response to furosemide during prolonged therapy. Kidney Int 1989, 36:682-689.
13. Domanski M, Norman J, Pitt B, et al.: Diuretic use, progressive heart failure, and death in patients in the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 2003, 42:705-708.
14. Butler J, Forman DE, Abraham WT, et al.: Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 2004, 147:331-338.
15. Kubo SH, Clark M, Laragh JH, et al.: Identification of normal neurohormonal activity in mild congestive heart failure and stimulating effects of upright posture and diuretics. Am J Cardiol 1987, 60:1322-1328.
16. McCurley JM, Hanlon SU, Wei S, et al.: Furosemide and the progression of left ventricular dysfunction in experimental heart failure. J Am Coll Cardiol 2004, 44:1301-1307.
17. Wilcox CS, Mitch WE, Kelly RA, et al.: Response of the kidney to furosemide. I. Effects of salt intake and renal compensation. J Lab Clin Med 1983, 102:450-458.
18. Reyes AJ, Taylor SH: Diuretics in cardiovascular therapy: the new clinicopharmacological bases that matter. Cardiovasc Drugs Ther 1999, 13:371-398.
19. Vargo DL, Kramer WG, Black PK, et al.: Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther 1995, 57:601-609.
20. Brater DC: Diuretic therapy. N Engl J Med 1998, 339:387-395.
21. Stroobandt R, Dodion L, Kesteloot H: Clinical efficacy of torasemide, a new diuretic agent, in patients with acute heart failure: a double blind comparison with furosemide. Arch Int Pharmacodyn Ther 1982, 260:151-158.
22. Muller K, Gamba G, Jaquet F, Hess B: Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV - efficacy and quality of life. Eur J Heart Fail 2003, 5:793-801.
23. Lopez B, Querejeta R, Gonzalez A, et al.: Effects of loop diuretics on yocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol 2004, 43:2028-2035.
24. Noe LL, Vreeland MG, Pezzella SM, Trotter JP: A pharmacoeconomic assessment of torsemide and furosemide in the treatment of patients with congestive heart failure. Clin Ther 1999, 21:854-866.
25. Ellison DH: Diuretic therapy and resistance in congestive heart failure. Cardiology 2001, 96:132-143.
26. Sigurd B, Olesen KH, Wennevold A: The supra-additive natriuretic effect addition of bendroflumethiazide and bumetanide in congestive heart failure: permutation trial tests in patients in long-term treatment with bumetanide. Am Heart J 1975, 89:163-170.
27. Ellison DH: The physiologic basis of diuretic synergism: its role in treating dimetic resistance. Ann Intern Med 1991, 114:887-894.
28. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group [no authors listed]. JAMA 1991, 265:3255-3266.
29. Pitt B, Remme W, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.
30. Weber KT, Brilla CG: Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 1991, 83:1849-1865.
31. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALESI). The RALES Investigators [no authors listed]. Am J Cardiol 1996, 78:902-907.
32. Stewart JH, Edwards KD: Clinical comparison of frusemide with bendrofluazide, mersalyl, and ethacrynic acid. Br Med J 1965, 2:1277-1281.
33. de Gasparo M, Joss U, Ramjoué HP, et al.: Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pbarmacol Exp Ther 1987, 240:650-656.
34. Lucas C, Johnson W, Hamilton MA, et al.: Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J 2000, 140:840-847.
35. Heywood JT: Clinical predictors of worsening renal function in patients hospitalized for heart failure. Circulation 2005, 112:11-589.
36. Butman SM, Ewy GA, Standen JR, et al.: Bedside cardiovascular examination in patients with severe chronic heart failure: importance of rest or inducible jugular venous distension. J Am Coll Cardiol 1993, 22:968-974.
37. DeWalt DA, Malone RM, Bryant ME, et al.: A heart failure self-management program for patients of all literacy levels: a randomized, controlled trial [ISRCTN115351701. BMC Health Serv Res 2006, 6:30.
38. Prasun MA, Kocheril AG, Klass PH, er al.: The effects of a sliding scale diuretic titration protocol in patients with heart failure. J Cardiovasc Nurs 2005, 20:62-70.
39. Galve E, Mallol A, Catalan R, et al.: Clinical and neurohumoral consequences of diuretic withdrawal in patients with chronic, stabilized heart failure and systolic dysfunction. Eur J Heart Fail 2005, 7:892-898.
40. Odemuyiwa O, Gilmartin J, Kenny D, Hall RJ: Captopril and the diuretic requirements in moderate and severe chronic heart failure. Eur Heart J 1989, 10:586-590.
41. Fonarow GC, Corday E; ADHERE Scientific Advisory Committee: Overview of acutely decompensated congestive heart failure (ADHF): a report from the ADHERE registry. Heart Fail Rev 2004, 9:179-185.
42. ADHERE: Acute Decompensated Heart Failure National Registry. 1st Quarter 2006 National Benchmark Report. Available at http://www.adhereregistry.com/nat.html. Accessed February 27, 2007.
43. Salvador DR, Rey NR, Ramos GC, Punzalan FE: Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev 2005, (20):CDO03178.
44. Lundvall J, Lanne T: Large capacity in man for effective plasma volume control in hypovolaemia via fluid transfer from tissue to blood. Acta Physiol Scand 1989, 137:513-520.
45. Boyle A, Sobotka PA: Redefining the therapeutic objective in decompensated heart failure: hemoconcentration as a surrogate for plasma refill rate. J Card Fail 2006, 12:247-249.
46. Binanay C, Califf RM, Hasselblad V, et al.: Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA 2005, 294:1625-1633.
47. Forman DE, Butler J, Wang Y, et al.: Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 2004, 43:61-67.
48. Heywood JT. The cardiorenal syndrome: lessons from the ADHERE database and treatment options. Heart Fail Rev 2004, 9:195-201.
49. Costanzo MR, Guglin ME, Saltzberg MT, et al.: Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007, 49:675-683.
50. Bart BA, Boyle A, Bank AJ, et al.: Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial. J Am Coll Cardiol 2005, 46:2043-2046.
51. Agostoni P, Marenzi G: Sustained benefit from ultrafiltration in moderate congestive heart failure. Cardiology 2001, 96:183-189.
52. Marenzi G, Grazi S, Giraldi F, et al.: Interrelation of humoral factors, hemodynamics, and fluid and salt metabolism in congestive heart failure: effects of extracorporeal ultrafiltration. Am J Med 1993, 94:49-56.
53. Jaski BE, Ha J, Denys BG, et al.: Peripherally inserted veno-venous ultrafiltration for rapid treatment of volume overloaded patients. J Card Fail 2003, 9:227-231.
54. Welch WJ: Adenosine Al receptor antagonists in the kidney: effects in fluid-retaining disorders. Curr Opin Pharmacol 2002, 2:165-170.
55. deGoma EM, Vagelos RH, Fowler MB, Ashley EA: Emerging therapies for the management of decompensated heart failure: from hench to bedside. J Am Coll Cardiol 2006, 48:2397-409.
56. Gottlieb SS, Brater DC, Thomas I, et al.: BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 2002, 105:1348-1353.
57. Nielsen S, Chou CL, Marples D, et al.: Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasma membrane. Proc Natl Acad Sci U S A 1995, 92:1013-1017.
58. Gheorghiade M, Gattis WA, O'Connor CM, et al.: Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004, 291:1963-1971.
59. Gheorghiade M, Orlandi C, Burnett JC, et al.: Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). J Card Fail 2005, 11:260-269.
60. IvyRose Holistic: The Structure of a Kidney Nephron. Available at http://www.ivy-rose.co.uk/Topics/Urinary_System_Nephron_Diagram.php. Accessed on March 4, 2007.